Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Konaten
Tests of reference samples showed that the batches covered by the decision do not meet the requirements for atomoxetine content, and batch 1311190 also fails the uniformity of mass parameter, which poses a real and direct risk to patients’ health. Potential effects: reduced treatment efficacy, risk of symptom worsening, possible complications resulting from improper dosing.
Palifren Long
This product does not meet the specified quality requirements due to a negative test result for paliperidone palmitate content and particle size analysis. Potential effects: lack of therapeutic efficacy or adverse reactions after parenteral administration.
Corhydron 25
Stability studies showed that the batch does not meet quality requirements (result above the limit for free hydrocortisone content), which according to the authority constitutes a real and direct threat to patients’ health or life. Potential effects: impaired treatment efficacy, unpredictable adverse reactions, complications.
Palifren Long
The National Medicines Institute found that the product did not meet quality requirements due to a negative test result for the parameters: paliperidone palmitate content and particle size analysis. Potential effects: impaired treatment effectiveness, adverse effects, complications.
Viglita
The product does not meet quality requirements due to an out-of-specification result for friability of uncoated tablets; the sample contained crushed, cracked or broken tablets. Potential effects: possible uneven dosing of the drug and reduced therapeutic efficacy.
Oekolp forte
Exceeding the established limit of an unknown impurity was found in batch 23000333, making it impossible to assess safety of use. The authority indicated a real risk to patients’ health and potentially life. Potential effects: poisoning, serious adverse reactions, life‑threatening events.
Oekolp forte
An exceedance of the acceptable content of an unknown impurity was found in batch 23000333, making it impossible to assess the safety of the medicine’s use; the authority indicated a real risk to patients’ health and potentially life. Potencjalne skutki: poisoning, unknown adverse reactions, threat to health or life.
Reparil Gel N
The application explained that the manufacturer is preparing documentation on the root cause of the non-conformity, implemented corrective and preventive actions, and identified violations of the product’s quality requirements. Potential effects: possible reduced treatment effectiveness or occurrence of unexpected adverse reactions.
Egoropal
The medicinal product does not meet quality requirements due to a negative test result for the particle size analysis parameter in the prolonged-release suspension for injection. Potential effects: abnormal dose release, reduced efficacy or increased risk of adverse reactions.
Egoropal
It was found that the product does not meet quality requirements due to a failed particle size analysis in the injectable suspension. Potential effects: possible altered drug release, lack of efficacy or unpredictable adverse reactions.
Zodgane
Test result out of specification for particle size distribution D(0.9) (batch 1254), indicating suspected failure to meet quality requirements. Potential effects: possible reduced efficacy of the medicine.
Ibuprofen Dr. Max
The product does not meet quality requirements due to a negative result for the loss on drying parameter; only a medicine compliant with the specification can be considered effective and safe. Potential effects: possibly reduced analgesic effect and uncertain treatment safety.
Qutiro
Suspected microbiological contamination of the infusion solution, linked with detection of Klebsiella pneumoniae ESBL in patients’ blood cultures and serious unexpected adverse reactions (chills, chest pain, convulsions). Potential effects: sepsis, severe systemic reactions, life-threatening conditions.
Qutiro
After Qutiro infusion, patients developed chills, chest pain and seizures; blood cultures grew Klebsiella pneumoniae ESBL, indicating infection and a real threat to health or life. Potential effects: sepsis, septic shock, severe complications, death.
Qutiro
In several patients after Qutiro infusion, chills, chest pain and convulsions occurred; blood cultures grew Klebsiella pneumoniae ESBL. A microbiological contamination of the sterile infusion product is suspected, posing a real threat to patients’ health or life. Potential effects: severe bloodstream infection, septic shock, life‑threatening complications.
Omegaflex special
An improperly made package seal allowed air and oxygen to enter the bag, which could change the medicine’s properties and lead to adverse health effects and a real risk to patients’ health and potentially also life. Potential effects: complications, lack of efficacy, possible severe reactions.
Omegaflex special
An improperly made seal of the outer bag allowed air and oxygen to enter, which could change the properties of the lipid emulsion and poses a real risk to patients’ health and life. Potential effects: complications during infusion, lack of treatment efficacy, adverse reactions.
ACC classic
The presence of solid particles from the sealing insert in the medicinal product in the form of an oral solution creates a high probability of swallowing them, which, depending on the size and shape of the particles, may lead to unpredictable, direct, negative health effects, potentially life‑threatening. Potential effects: irritation of the gastrointestinal tract, mechanical injuries, complications endangering health or life.
ACC classic
The presence of solid particles originating from the closure’s sealing insert has been detected in the oral solution. Swallowing them, depending on their size and shape, may lead to unpredictable adverse health effects. Potential effects: gastrointestinal irritation, mechanical complications, life-threatening conditions in extreme cases.
Auroverin MR
This batch does not meet the specified quality requirements due to a negative test result for the mebeverine hydrochloride release parameter. Potential effects: reduced effectiveness in treating intestinal disorders, possible worsening of disease symptoms.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.